Researchers at Helius are exploring the vast potential of cannabinoids in treating pain, sleep, anxiety and other chronic conditions. Future targets will extend beyond symptom relief into disease modification, particularly in the treatment of inflammatory and neurodegenerative conditions.
As the country’s largest, vertically-integrated medical cannabis business, Helius is developing state-of-the-art, GMP-certified facilities in Auckland encompassing a large-scale cultivation centre, an integrated extraction site, advanced cannabinoid research laboratories and pharmaceutical manufacturing operations.
“We’re proud to support New Zealand’s first medicinal cannabis summit. MedCan Summit 2020 will not only be a catalyst for New Zealand’s burgeoning industry, but a truly exciting and educational event for everyone. It’s great to have BioTechNZ leading the charge and unifying stakeholders to deliver a comprehensive and exciting programme,” said Paul Manning, Chief Executive Officer of Helius Therapeutics.
“Globally, I believe New Zealand will become a centre of excellence for medicinal cannabis innovation. MedCan 2020 will help launch and inspire this wonderful new industry.”
It holds a license to cultivate a prohibited plant for research purposes, including the cultivation of high THC cultivars.
The company recently purchased a 26-hectare greenfield site overlooking Lake Taupo to house its new facility, which will commence production in 2020 with an initial annual scaled production capacity of circa 17,000kg of dried flower for processing.
SETEK recently acquired a cannabis genetics company and a horticultural LED lighting company. Most recently, they signed a multi-year MoU with listed company, AFT Pharmaceuticals to work together in the research, development, commercialisation and distribution of cannabinoid-based medicines.
SETEK’s Advisory Board is headed by former Associate Health Minister, Hon Peter Dunne.
“MedCan Summit 2020 is a wonderful opportunity to dispel some of the misconceptions that surround medicinal cannabis and showcase just how profoundly it can impact people’s lives,” SETEK Chief Executive Mark Mees said.
“And that’s our company’s mission – to change lives for the better with affordable, GMP grade, 100% New Zealand organic-certified cannabis medicines. BioTechNZ will organise a tremendous event, and we are delighted to be a MedCan 2020 Gold Sponsor.”
AJ Park is one of Australasia’s leading full-service intellectual property (IP) law firms. With offices in Auckland and Wellington, we have one of the largest, most experienced teams of IP experts in the region. For over 128 years, we’ve helped companies and individuals identify, develop, protect, commercialise, manage, and enforce their IP rights in Australasia and throughout the world.
Our practice groups are organised around our technical expertise in patents, trade marks, commercial and litigation services. Within our practice groups, we have expertise in a range of industries, including agribiotech and therapeutic goods. Our teams work collaboratively to ensure we provide clients with clear and timely advice that helps them maximise the value of their IP. AJ Park acts for a wide range of clients, from solo inventors, entrepreneurs and SMEs, to government institutions, multinationals and major listed companies. We are proud to represent a large number of innovative and iconic companies in New Zealand, as well as over a third of the global Fortune 500.
“AJ Park is committed to helping New Zealand businesses understand and leverage intellectual property. The establishment of a medicinal cannabis scheme in New Zealand is an exciting opportunity for innovation. We are proud to be a silver sponsor of the inaugural MedCan Summit 2020 and to help the medicinal cannabis sector develop and protect their brands, products, ideas and innovations.”
Shimadzu’s Cannabis and Hemp Testing Solutions cover a broad range of applications, from accurate potency testing and terpene profiling to contaminant testing for pesticides, residual solvents, heavy metals, and mycotoxins/aflatoxins. We supply the instruments, methods and experience necessary to get you up and running quickly.
Shimadzu scientific instruments have been applied to natural products, food sciences, pharmaceuticals and environmental testing for decades. Whether you are a chromatography expert or a novice, our platforms and training ensure that your laboratory will generate quality results from a wide variety of cannabis samples. Our easy to use platforms save you time and money, maximizing the profits of your laboratory. Shimadzu can help you with your QA/QC testing, peak harvesting analysis and cannabis research.
Spectrum Therapeutics provides medicinal cannabis to patients in Australia and around the world. In addition to a consistent supply of lab-tested medicine, you can rely on us to keep up to date with clear and accurate information. We are driven by a strong focus on quality, evidence, safety and education. As we invest in research, our goal is to deliver innovative medicine that raise the bar on therapy and outcomes for patients everywhere.
If you are a patient wanting information about medicinal cannabis, you should consult with your Healthcare Professional.
Spectrum Therapeutics™ medicinal cannabis products are not registered in New Zealand. More information is available at medsafe.govt.nz
“Spectrum Therapeutics’ sponsorship of the MedCan Summit represents our commitment to New Zealand health care professionals and their patients. Our top priorities include patient access, quality medicines and education. MedCan 2020 will bring global experts to Auckland, so the current scientific evidence on medicinal cannabis is shared with health practitioners, researchers, regulators and industry stakeholders,” said Ben Quirin, Regional Managing Director, APAC, Canopy Growth.
Cannasouth is a biopharmaceutical company dedicated to medicinal cannabis research and product development for prescribers and patients in New Zealand.
Based in the Waikato, we have established state of the art laboratories, research and cultivation facilities. Our goal is the development of next-generation cannabinoid therapeutics to support patients health outcomes and improve their quality of life.